Form 4: Acadia Pharmaceuticals Executive Brendan Teehan Reports Stock Transactions

EVP, COO, and Head of Commercial Brendan Teehan of Acadia Pharmaceuticals reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• On April 5, 2024, Brendan Teehan, EVP, COO, and Head of Commercial at Acadia Pharmaceuticals, vested 5,024 restricted stock units, each representing a contingent right to receive one share of Acadia's common stock.
• Following the vesting, Mr. Teehan sold 2,568 shares of common stock on April 8, 2024, at a weighted average price of $17.87 per share.
• The sales were mandatory and intended to cover withholding taxes and tax-related items imposed by Acadia Pharmaceuticals in connection with the vesting of the restricted stock units.
• After these transactions, Mr. Teehan directly owns 38,796 shares of Acadia Pharmaceuticals common stock and 10,048 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation and stock transactions. It doesn't indicate any significant positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time.
• The sale of shares to cover tax obligations upon vesting is a common practice among executives.
• The transactions are reported to the SEC in compliance with Section 16(a) of the Securities Exchange Act of 1934.

Key Dates